Table 1 Incidence of arthroplasty in OA patients with medications
Study | Study design | Follow-up (month) | Sites of OA | NO. of arthroplasty (n) | Incidence (%) |
|---|---|---|---|---|---|
Intra-articular corticosteroids | Â | Â | Â | Â | Â |
 Ward 2021 [20] | Cohort study | 67 | Knee | 139,529/387,702 | 35.99 |
 Zeng 2019 [23] | Cohort study | 48 | Knee | 33/148 | 22.30 |
 Delbarre 2017 [36] | Cohort study | 44 | Knee | 366/5306 | 6.90 |
 Walter 2019 [24] | Cohort study | NA | Hip | 49/113 | 43.36 |
 Villoutreix 2006 [54] | Cohort study | ≥ 6 | Hip | 27/28 | 96.43 |
 Pope 2008 [51] | Case–control study | 24 | Hip | 26/36 | 72.22 |
 Pope 2008 [51] | Case–control study | 24 | Knee | 46/124 | 37.10 |
Hyaluronic acid | Â | Â | Â | Â | Â |
 Ward 2021 [20] | Cohort study | 67 | Knee | 73,436/187,268 | 39.21 |
 Concoff 2021 [21] | Cohort study | 24 | Knee | 52,212/181,631 | 28.75 |
 Ong 2019 [22] | Cohort study | 24 | Knee | 8315/56,093 | 14.82 |
 Dasa2018 [30] | Cohort study | 36 | Knee | 44/887 | 4.96 |
 Bowman 2018 [31] | Cohort study | 27 | Knee | 20/102 | 19.61 |
 Annaniemi 2018 [32] | Cohort study | 17 | Knee | 31/86 | 36.05 |
 Delbarre 2016 [39] | Cohort study | 42 | Knee | 1296/9476 | 13.68 |
 Turajane 2009 [48] | Cohort study | 54 | Knee | 52/183 | 28.42 |
 Migliore 2012 [44] | Cohort study | 48 | Hip | 32/176 | 18.18 |
 van den Bekerom 2008 [49] | Cohort study | 36 | Hip | 59/120 | 49.17 |
 Gaston 2007 [53] | Cohort study | 6 | Hip | 4/15 | 26.67 |
 Turajane 2017 [48] | RCT | 12 | Knee | 3/20 | 15.00 |
 Ong 2019b [22] | Cohort study | 24 | Knee | 8315/56,093 | 14.82 |
 Boutefnouchet 2017 [37] | Cohort study | 60 | Knee | 26/82 | 31.70 |
 Migliore 2012 [43] | Cohort study | 60 | Hip | 84/224 | 37.50 |
Bisphosphonates | Â | Â | Â | Â | Â |
 Neogi 2018 [27] | Cohort study | 3 | Knee | 138/2006 | 6.88 |
 Fu 2017 [35] | Cohort study | 14 | Knee | 595/16,276 | 3.66 |
 Turajane 2017 [33] | RCT | 12 | Knee | 3/20 | 15.00 |
 Nishii 2013 [42] | RCT | 24 | Hip | 7/30 | 23.33 |
SYSADOA | Â | Â | Â | Â | Â |
 Bruyere 2008 [52] | Cohort study | 62 | Knee | 9/144 | 6.25 |
 Dorais 2018 [29] | Case–control study | 52 | Knee | 88/283 | 31.10 |
 Wildi 2011 [46] | RCT | 6 | Knee | 0/35 | 0.00 |
 Rozendaal 2008 [50] | RCT | 24 | Hip | 13/111 | 11.71 |
NSAIDs | Â | Â | Â | Â | Â |
 Hafezi-Nejad 2016 [38] | Cohort study | 96 | Knee | 29/173 | 16.76 |
 Reijman 2005 [55] | Cohort study | 79 | Knee | 13/874 | 1.49 |
 Reijman 2005 [55] | Cohort study | 79 | Hip | 116/2514 | 4.61 |
 Gossec 2005 [56] | Cohort study | 24 | Hip | 139/331 | 41.99 |
 Dorais 2018 [29] | Case–control study | 52 | Knee | 101/276 | 36.59 |
 Klop 2012 [45] | Case–control study | 91 | Knee | 706/996 | 70.88 |
 Raynauld 2011 [47] | Case–control study | 56 | Knee | 18/123 | 14.63 |
 Arends 2017 [41] | Case–control study | ≤ 6 | Knee/hip | 105/266 | 39.47 |
 Klop 2012 [45] | Case–control study | 91 | Hip | 1099/1586 | 69.29 |
 Pope 2008 [51] | Case–control study | 24 | Knee/hip | 366/542 | 67.53 |
 Balanescu 2012 [59] | RCT | 8 | Knee/hip | 1/152 | 0.66 |
 Schnitzer 2015 [40] | RCT | 16 | Knee/hip | 25/539 | 4.64 |
 Ekman 2014 [58] | RCT | 6 | Knee/hip | 1/211 | 0.47 |
 ALHO 1988 [57] | RCT | 3–6 | Hip | 38/252 | 15.08 |